Dave S B Hoon

List of Publications by Year
in descending order

324	25,850	5876	8138
papers	citations	81 h-index	148 g-index

331	331	331	32256
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer, 2011, 11, 426-437.	12.8	2,372
2	A Landscape of Driver Mutations in Melanoma. Cell, 2012, 150, 251-263.	13.5	2,247
3	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine, 2017, 376, 2211-2222.	13.9	1,087
4	Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, 2022, 185, 881-895.e20.	13.5	605
5	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS ONE, 2015, 10, e0140712.	1.1	580
6	Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature, 2012, 488, 231-235.	13.7	460
7	Direct Serum Assay for MicroRNA-21 Concentrations in Early and Advanced Breast Cancer. Clinical Chemistry, 2011, 57, 84-91.	1.5	420
8	Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine. Annals of Surgery, 1992, 216, 463-482.	2.1	360
9	Chemokine Receptor CXCR4 Expression in Colorectal Cancer Patients Increases the Risk for Recurrence and for Poor Survival. Journal of Clinical Oncology, 2005, 23, 2744-2753.	0.8	348
10	MBNL proteins repress ES-cell-specific alternative splicing and reprogramming. Nature, 2013, 498, 241-245.	13.7	326
11	An Alternative Splicing Switch Regulates Embryonic Stem Cell Pluripotency and Reprogramming. Cell, 2011, 147, 132-146.	13.5	325
12	Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum. Journal of Clinical Oncology, 2006, 24, 4270-4276.	0.8	300
13	Increased Integrity of Free Circulating DNA in Sera of Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU Repeats. Clinical Chemistry, 2006, 52, 1062-1069.	1.5	280
14	Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenvironment, 2009, 2, 205-214.	3.1	265
15	Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse Transcriptaseâ€“Polymerase Chain Reaction in Early-Stage Melanoma Patients. Journal of Clinical Oncology, 1999, 17, 3238-3244.	0.8	260
16	Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma. Annals of Surgery, 2003, 238, 538-550.	2.1	249
17	Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene, 2004, 23, 4014-4022.	2.6	231
18	S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites. Cancer Cell, 2012, 21, 642-654.	7.7	229

#	Article	IF	Citations
19	Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas. Clinical Cancer Research, 2004, 10, 1753-1757.	3.2	208
20	FOXC1 Is a Potential Prognostic Biomarker with Functional Significance in Basal-like Breast Cancer. Cancer Research, 2010, 70, 3870-3876.	0.4	202
21	STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth. Cell Metabolism, 2020, 31, 148-161.e5.	7.2	201
22	BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4321-4326.	3.3	200
23	Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7765-7769.	3.3	198
24	The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 2006, 12, 4605-4613.	3.2	197
25	Molecular Staging of Early Colon Cancer on the Basis of Sentinel Node Analysis: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2001, 19, 1128-1136.	0.8	195
26	CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma. Clinical Cancer Research, 2009, 15, 1801-1807.	3.2	182
27	Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics, 2011, 6, 388-394.	1.3	180
28	c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clinical Cancer Research, 2003, 9, 1480-8.	3.2	180
29	CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells. Clinical Cancer Research, 2004, 10, 2351-2358.	3.2	164
30	Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving Biochemotherapy. Journal of Clinical Oncology, 2005, 23, 9351-9358.	0.8	158
31	Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy. Clinical Cancer Research, 2007, 13, 2068-2074.	3.2	158
32	Chemokine Receptor CXCR4 Expression in Patients With Melanoma and Colorectal Cancer Liver Metastases and the Association With Disease Outcome. Annals of Surgery, 2006, 244, 113-120.	2.1	154
33	Distinct Hypermethylation Profile of Primary Breast Cancer Is Associated with Sentinel Lymph Node Metastasis. Clinical Cancer Research, 2005, 11, 2156-2162.	3.2	147
34	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget, 2015, 6, 3211-3224.	0.8	145
35	Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. Clinical Cancer Research, 2008, 14, 638-645.	3.2	141
36	Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes. Annals of Surgery, 2002, 236, 438-449.	2.1	137

#	Article	IF	Citations
37	Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients. Journal of Clinical Oncology, 2004, 22, 2671-2680.	0.8	137
38	Prognostic Impact of Micrometastases in Colon Cancer. Annals of Surgery, 2007, 246, 568-577.	2.1	135
39	LINE-1 Hypomethylation During Primary Colon Cancer Progression. PLoS ONE, 2011, 6, e18884.	1.1	128
40	IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nature Communications, 2015, 6, 8746.	5.8	125
41	B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma. Journal of Investigative Dermatology, 2013, 133, 2050-2058.	0.3	121
42	Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Research, 2003, 63, 1639-43.	0.4	119
43	B Cells Promote Tumor Progression via STAT3 Regulated-Angiogenesis. PLoS ONE, 2013, 8, e64159.	1.1	118
44	B7â€“H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis. Annals of Surgery, 2010, 252, 1044-1051.	2.1	117
45	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	2.9	117
46	Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nature Medicine, 2017, 23, 1319-1330.	15.2	116
47	Anti-Tyrosinase-Related Protein-2 Immune Response in Vitiligo Patients and Melanoma Patients Receiving Active-Specific Immunotherapy. Journal of Investigative Dermatology, 1998, 111, 1034-1039.	0.3	115
48	Multimarker Circulating DNA Assay for Assessing Blood of Prostate Cancer Patients. Clinical Chemistry, 2009, 55, 559-567.	1.5	112
49	Estrogen Receptor-Î± Methylation Predicts Melanoma Progression. Cancer Research, 2006, 66, 6692-6698.	0.4	111
50	Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles. Nucleic Acids Research, 2015, 43, e44-e44.	6.5	111
51	RNA Melanoma Vaccine: Induction of Antitumor Immunity by Human Glycoprotein 100 mRNA Immunization. Human Gene Therapy, 1999, 10, 2719-2724.	1.4	108
52	Epigenetic Up-regulation of C-C Chemokine Receptor 7 and C-X-C Chemokine Receptor 4 Expression in Melanoma Cells. Cancer Research, 2005, 65, 1800-1807.	0.4	108
53	Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Molecular Cancer Therapeutics, 2008, 7, 3642-3653.	1.9	108
54	Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. Journal of Clinical Medicine, 2015, 4, 1890-1907.	1.0	107

#	Article	IF	Citations
55	The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes. Clinical Cancer Research, 2018, 24, 4126-4136.	3.2	105
56	Epigenetic Inactivation of ID4 in Colorectal Carcinomas Correlates with Poor Differentiation and Unfavorable Prognosis. Clinical Cancer Research, 2004, 10, 7475-7483.	3.2	104
57	Prediction of Disease Outcome in Melanoma Patients by Molecular Analysis of Paraffin-Embedded Sentinel Lymph Nodes. Journal of Clinical Oncology, 2003, 21, 3566-3572.	0.8	103
58	Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Review of Molecular Diagnostics, 2013, 13, 827-844.	1.5	103
59	Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer. Nature Communications, 2020, 11, 320.	5.8	103
60	Prognostic Relevance of Occult Nodal Micrometastases and Circulating Tumor Cells in Colorectal Cancer in a Prospective Multicenter Trial. Clinical Cancer Research, 2008, 14, 7391-7396.	3.2	101
61	Regulation of RUNX3 Tumor Suppressor Gene Expression in Cutaneous Melanoma. Clinical Cancer Research, 2009, 15, 2988-2994.	3.2	101
62	Higher Amount of Free Circulating DNA in Serum than in Plasma Is Not Mainly Caused by Contaminated Extraneous DNA during Separation. Annals of the New York Academy of Sciences, 2006, 1075, 299-307.	1.8	100
63	UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. Cell, 2019, 176, 505-519.e22.	13.5	100
64	Detection of Circulating Tumor Cells in Early-Stage Breast Cancer Metastasis to Axillary Lymph Nodes. Clinical Cancer Research, 2007, 13, 4105-4110.	3.2	99
65	Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients. Clinical Chemistry, 2005, 51, 981-988.	1.5	98
66	Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene, 2005, 24, 4721-4727.	2.6	96
67	Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial. Journal of Clinical Oncology, 2005, 23, 8057-8064.	0.8	96
68	Sentinel Lymph Node Molecular Ultrastaging in Patients With Melanoma: A Systematic Review and Meta-Analysis of Prognosis. Journal of Clinical Oncology, 2007, 25, 1588-1595.	0.8	96
69	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Molecular Genetics, 2014, 23, 226-238.	1.4	96
70	The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer, 1995, 76, 533-535.	2.0	93
71	Molecular mechanisms of metastasis. Cancer and Metastasis Reviews, 2006, 25, 203-220.	2.7	92
72	Enhanced Survival Associated with Vitiligo Expression during Maintenance Biotherapy for Metastatic Melanoma. Journal of Investigative Dermatology, 2006, 126, 2658-2663.	0.3	90

#	Article	IF	Citations
73	Association of Circulating Tumor Cells with Serum Tumor-Related Methylated DNA in Peripheral Blood of Melanoma Patients. Cancer Research, 2006, 66, 6111-6117.	0.4	90
74	The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. Journal of Investigative Dermatology, 2015, 135, 2464-2474.	0.3	90
75	Allelic Imbalance of 12q22â€“23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma. Cancer Research, 2004, 64, 2245-2250.	0.4	89
76	Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. European Journal of Cancer, 2002, 38, 977-985.	1.3	86
77	Quantification of Circulating DNA in the Plasma and Serum of Cancer Patients. Annals of the New York Academy of Sciences, 2004, 1022, 17-24.	1.8	85
78	The G691S RET Polymorphism Increases Glial Cell Lineâ€“Derived Neurotrophic Factorâ€“Induced Pancreatic Cancer Cell Invasion by Amplifying Mitogen-Activated Protein Kinase Signaling. Cancer Research, 2005, 65, 11536-11544.	0.4	85
79	Prospective Multicenter Trial of Staging Adequacy in Colon Cancer. Archives of Surgery, 2006, 141, 527.	2.3	85
80	Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Research, 2008, 10, R46.	2.2	85
81	Quantification of LINE1 in Circulating DNA as a Molecular Biomarker of Breast Cancer. Annals of the New York Academy of Sciences, 2008, 1137, 171-174.	1.8	83
82	Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma. Annals of Surgery, 2012, 255, 357-362.	2.1	83
83	Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut, 2006, 55, 1598-1605.	6.1	82
84	Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19. Nature Biotechnology, 2022, 40, 110-120.	9.4	81
85	Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Research, 2003, 63, 441-8.	0.4	80
86	Epigenetic Regulation of Cancer Stem Cell Genes in Triple-Negative Breast Cancer. American Journal of Pathology, 2012, 181, 257-267.	1.9	79
87	Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitorâ€“Resistant Cutaneous Melanomas. Journal of Investigative Dermatology, 2015, 135, 532-541.	0.3	79
88	Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Molecular Oncology, 2016, 10, 450-463.	2.1	79
89	Epigenetic profiling for the molecular classification of metastatic brain tumors. Nature Communications, 2018, 9, 4627.	5.8	79
90	Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial. Journal of Clinical Oncology, 2012, 30, 3819-3826.	0.8	77

#	Article	IF	Citations
91	AIM1 and LINE-1 Epigenetic Aberrations in Tumor and Serum Relate to Melanoma Progression and Disease Outcome. Journal of Investigative Dermatology, 2012, 132, 1689-1697.	0.3	77
92	Molecular Strategy for Detecting Metastatic Cancers with Use of Multiple Tumor-specific MAGE-A Genes. Clinical Chemistry, 2001, 47, 505-512.	1.5	76
93	A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer, 2011, 117, 2599-2607.	2.0	75
94	Assessment of DNA methylation status in early stages of breast cancer development. British Journal of Cancer, 2013, 108, 2033-2038.	2.9	75
95	The metastatic microenvironment: Brainâ€residing melanoma metastasis and dormant micrometastasis. International Journal of Cancer, 2012, 131, 1071-1082.	2.3	74
96	Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Research and Treatment, 2012, 134, 1103-1114.	1.1	72
97	RASAL2 activates RAC1 to promote triple-negative breast cancer progression. Journal of Clinical Investigation, 2014, 124, 5291-5304.	3.9	72
98	A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget, 2015, 6, 7053-7064.	0.8	72
99	mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen-Specific Monoclonal Antibody Beads. Clinical Chemistry, 2009, 55, 757-764.	1.5	71
100	Detection of metastatic breast cancer by Î²-hCG polymerase chain reaction. , 1996, 69, 369-374.		70
101	Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. International Journal of Cancer, 2005, 117, 1032-1038.	2.3	69
102	Lymphatic Mapping Establishes the Role of BRAF Gene Mutation in Papillary Thyroid Carcinoma. Annals of Surgery, 2006, 244, 799-804.	2.1	69
103	Kinesin 18A expression: Clinical relevance to colorectal cancer progression. International Journal of Cancer, 2011, 129, 2543-2552.	2.3	69
104	Epigenetic biomarkers in skin cancer. Cancer Letters, 2014, 342, 170-177.	3.2	69
105	Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR. , 1998, 79, 645-651.		68
106	False Negative Sentinel Lymph Node Biopsies in Melanoma May Result From Deficiencies in Nuclear Medicine, Surgery, or Pathology. Annals of Surgery, 2008, 247, 1003-1010.	2.1	67
107	Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunology, Immunotherapy, 2018, 67, 1777-1788.	2.0	67
108	Circulating DNA Microsatellites: Molecular Determinants of Response to Biochemotherapy in Patients With Metastatic Melanoma. Journal of the National Cancer Institute, 2004, 96, 152-156.	3.0	66

#	Article	IF	Citations
109	Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma. Clinical Cancer Research, 2010, 16, 2402-2408.	3.2	66
110	Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer. Journal of Clinical Oncology, 2007, 25, 4887-4894.	0.8	65
111	DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 2014, 16, 1499-1509.	0.6	65
112	CCR4 is a determinant of melanoma brain metastasis. Oncotarget, 2017, 8, 31079-31091.	0.8	65
113	Pathologic Examination of Sentinel Lymph Node for Breast Carcinoma. World Journal of Surgery, 2001, 25, 798-805.	0.8	64
114	LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget, 2017, 8, 11906-11916.	0.8	64
115	Detection of Differentially Expressed Proteins in Early-Stage Melanoma Patients Using SELDI-TOF Mass Spectrometry. Annals of the New York Academy of Sciences, 2004, 1022, 317-322.	1.8	63
116	LC/MS-Based Quantitative Proteomic Analysis of Paraffin-Embedded Archival Melanomas Reveals Potential Proteomic Biomarkers Associated with Metastasis. PLoS ONE, 2009, 4, e4430.	1.1	62
117	Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene, 2009, 28, 3058-3068.	2.6	62
118	Polyvalent Melanoma Vaccine Improves Survival of Patients with Metastatic Melanoma. Annals of the New York Academy of Sciences, 1993, 690, 120-134.	1.8	61
119	The clinical significance ofMAGEA3 expression in pancreatic cancer. International Journal of Cancer, 2006, 118, 2269-2275.	2.3	61
120	Chemokineâ€“chemokine receptor axes in melanoma brain metastasis. Immunology Letters, 2010, 130, 107-114.	1.1	61
121	miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clinical Epigenetics, 2018, 10, 64.	1.8	60
122	Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. Cellular Immunology, 1988, 111, 410-419.	1.4	59
123	Circulating Nucleic Acids and Proteomics of Plasma/Serum: Clinical Utility. Annals of the New York Academy of Sciences, 2004, 1022, 1-8.	1.8	59
124	Enhancement of Immunity by a DNA Melanoma Vaccine against TRP2 with CCL21 as an Adjuvant. Molecular Therapy, 2006, 13, 194-202.	3.7	59
125	Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11121-11126.	3.3	57
126	Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas. Neurosurgical Review, 2014, 37, 367-380.	1.2	57

#	Article	IF	Citations
127	Allelic Imbalance on 12q22-23 in Serum Circulating DNA of Melanoma Patients Predicts Disease Outcome. Cancer Research, 2004, 64, 4085-4088.	0.4	56
128	Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma Patients. Journal of Investigative Dermatology, 1998, 111, 662-667.	0.3	54
129	Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget, 2018, 9, 8206-8222.	0.8	54
130	Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells. International Journal of Cancer, 1987, 40, 12-17.	2.3	53
131	Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers. European Urology Focus, 2017, 3, 265-272.	1.6	53
132	Molecular Clonality of In-Transit Melanoma Metastasis. American Journal of Pathology, 2001, 158, 1371-1378.	1.9	52
133	Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.. Clinical Cancer Research, 2006, 12, 1137-1143.	3.2	52
134	A New Melanoma Antigen Fatty Acidâ€“Binding Protein 7, Involved in Proliferation and Invasion, Is a Potential Target for Immunotherapy and Molecular Target Therapy. Cancer Research, 2006, 66, 4443-4449.	0.4	51
135	PTEN/MMAC1 Mutation and Frequent Loss of Heterozygosity Identified in Chromosome 10q in a Subset of Hepatocellular Carcinomas. Japanese Journal of Cancer Research, 2000, 91, 287-292.	1.7	50
136	Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell and Melanoma Research, 2015, 28, 82-93.	1.5	50
137	Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated With a Melanoma Vaccine. Journal of Clinical Oncology, 2003, 21, 2558-2563.	0.8	49
138	Peptide nucleic acid clamp PCR: A novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. International Journal of Cancer, 2004, 111, 409-414.	2.3	49
139	Hypoxia induces HIF1Î±-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nature Communications, 2022, 13, .	5.8	48
140	Growth Inhibition and Modulation of Cell Markers of Melanoma by S-Allyl Cysteine. Oncology, 1993, 50, 63-69.	0.9	47
141	X-Linked Inhibitor of Apoptosis Protein Expression Level in Colorectal Cancer Is Regulated by Hepatocyte Growth Factor/C-Met Pathway via Akt Signaling. Clinical Cancer Research, 2005, 11, 7621-7628.	3.2	47
142	Genome-Wide Characterization of Circulating Tumor Cells Identifies Novel Prognostic Genomic Alterations in Systemic Melanoma Metastasis. Clinical Chemistry, 2014, 60, 873-885.	1.5	47
143	Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas. Journal of Cellular Biochemistry, 1996, 62, 443-453.	1.2	45
144	Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. Cancer Letters, 2015, 361, 86-96.	3.2	45

#	Article	IF	Citations
145	Detection of Mitochondrial DNA Alterations in Plasma of Malignant Melanoma Patients. Annals of the New York Academy of Sciences, 2004, 1022, 50-54.	1.8	44
146	The metastatic microenvironment: Claudinâ€1 suppresses the malignant phenotype of melanoma brain metastasis. International Journal of Cancer, 2015, 136, 1296-1307.	2.3	44
147	Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clinical Cancer Research, 2003, 9, 1427-35.	3.2	44
148	Proteomic Profiling of Primary Breast Cancer Predicts Axillary Lymph Node Metastasis. Cancer Research, 2006, 66, 11825-11830.	0.4	43
149	Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. British Journal of Cancer, 2013, 109, 3073-3083.	2.9	43
150	Active specific immunotherapy in malignant melanoma. Journal of Surgical Oncology, 1989, 5, 420-425.	1.4	41
151	Aberrant Expression of Gangliosides in Human Renal Cell Carcinomas. Journal of Urology, 1993, 150, 2013-2018.	0.2	41
152	The regulatory effect of adherent cells on lymphokine activated killer cells. Cellular Immunology, 1987, 110, 365-378.	1.4	40
153	Molecular Upstaging Based on Paraffin-Embedded Sentinel Lymph Nodes. Annals of Surgery, 2011, 253, 116-122.	2.1	40
154	Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Review of Molecular Diagnostics, 2015, 15, 647-664.	1.5	40
155	Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. Clinical and Experimental Metastasis, 2012, 29, 729-736.	1.7	39
156	Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clinical Cancer Research, 2016, 22, 3016-3024.	3.2	39
157	Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-Î³ retroviral vector in melanoma patients. Cancer Gene Therapy, 2000, 7, 1220-1230.	2.2	38
158	Alternative splicing and cancer metastasis: prognostic and therapeutic applications. Clinical and Experimental Metastasis, 2018, 35, 393-402.	1.7	38
159	Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. Cancer Research, 2019, 79, 760-772.	0.4	38
160	Anti-Idiotype Monoclonal Antibody Carrying the Internal Image of Ganglioside GM3. Journal of the National Cancer Institute, 1990, 82, 1757-1760.	3.0	37
161	Molecular mechanisms of metastasis. Journal of Surgical Oncology, 2011, 103, 508-517.	0.8	37
162	Lentivirus-induced â€˜Smartâ€™ dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. Gene Therapy, 2015, 22, 707-720.	2.3	37

#	Article	IF	Citations
163	Detection of MAGE-A3 in breast cancer patientsâ€™ sentinel lymph nodes. British Journal of Cancer, 2001, 85, 1340-1346.	2.9	36
164	Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma. Oncogene, 2004, 23, 8292-8300.	2.6	36
165	Epigenetic Analysis of Body Fluids and Tumor Tissues: Application of a Comprehensive Molecular Assessment for Early-Stage Breast Cancer Patients. Annals of the New York Academy of Sciences, 2006, 1075, 211-221.	1.8	36
166	Ganglioside GM2/GD2 Synthetase mRNA Is a Marker for Detection of Infrequent Neuroblastoma Cells in Bone Marrow. American Journal of Pathology, 2001, 159, 493-500.	1.9	35
167	DNA Methylation Index and Methylation Profile of Invasive Ductal Breast Tumors. Journal of Molecular Diagnostics, 2012, 14, 613-622.	1.2	35
168	Genomeâ€“Wide Hypomethylation and Specific Tumor-Related Gene Hypermethylation are Associated with Esophageal Squamous Cell Carcinoma Outcome. Journal of Thoracic Oncology, 2015, 10, 509-517.	0.5	35
169	Modulation of human macrophage functions by gangliosides. Immunology Letters, 1989, 20, 269-275.	1.1	34
170	Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. , 1998, 82, 309-316.		34
171	Induction of a Systemic Immune Response by a Polyvalent Melanoma-Associated Antigen DNA Vaccine for Prevention and Treatment of Malignant Melanoma. Molecular Therapy, 2002, 5, 291-299.	3.7	34
172	Synthesis of universal unmethylated control DNA by nested whole genome amplification with Ï•29 DNA polymerase. Biochemical and Biophysical Research Communications, 2005, 329, 219-223.	1.0	34
173	Heterogeneous epigenetic regulation ofTIMP3in prostate cancer. Epigenetics, 2012, 7, 1279-1289.	1.3	34
174	The metastatic microenvironment: Melanomaâ€“microglia crossâ€talk promotes the malignant phenotype of melanoma cells. International Journal of Cancer, 2019, 144, 802-817.	2.3	34
175	Protective immunization against melanoma by gp100 DNAâ€“HVJ-liposome vaccine. Gene Therapy, 1999, 6, 1768-1773.	2.3	33
176	Quantitative Analysis of Methylation of Genomic Loci in Early-Stage Rectal Cancer Predicts Distant Recurrence. Journal of Clinical Oncology, 2008, 26, 2327-2335.	0.8	33
177	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-ÎºB Pathway in Melanoma. Clinical Cancer Research, 2017, 23, 4831-4842.	3.2	33
178	Molecular Detection of Metastatic Melanoma Cells in Cerebrospinal Fluid in Melanoma Patients. Journal of Investigative Dermatology, 2001, 117, 375-378.	0.3	32
179	Progression of cutaneous melanoma: implications for treatment. Clinical and Experimental Metastasis, 2012, 29, 775-796.	1.7	32
180	MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in MetastaticÂMelanoma. Journal of Investigative Dermatology, 2017, 137, 1955-1964.	0.3	32

#	Article	IF	Citations
181	Sequestosome 1 (SQSTM1) Mutations in Pagetâ€™s Disease of Bone from the United States. Calcified Tissue International, 2008, 82, 271-277.	1.5	31
182	Human High Molecular Weightâ€“Melanoma-Associated Antigen: Utility for Detection of Metastatic Melanoma in Sentinel Lymph Nodes. Clinical Cancer Research, 2008, 14, 3401-3407.	3.2	31
183	Circulating nucleic acids in plasma and serum: past, present and future. Current Opinion in Molecular Therapeutics, 2004, 6, 273-8.	2.8	31
184	Detection of Î²-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. , 1996, 65, 454-459.		30
185	Aberrant Fatty Acid-Binding Protein-7 Gene Expression in Cutaneous Malignant Melanoma. Journal of Investigative Dermatology, 2010, 130, 221-229.	0.3	30
186	Circulating tumor cells: Cancerâ€™s deadly couriers. Physics Today, 2014, 67, 26-30.	0.3	30
187	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment. Cell Reports, 2017, 18, 2331-2342.	2.9	30
188	Assessment of Methylation Events during Colorectal Tumor Progression by Absolute Quantitative Analysis of Methylated Alleles. Molecular Cancer Research, 2007, 5, 461-471.	1.5	29
189	B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma. Laboratory Investigation, 2019, 99, 1117-1129.	1.7	29
190	Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. Cellular Immunology, 1992, 139, 411-425.	1.4	28
191	Comparative Analysis of Mesenteric and Peripheral Blood Circulating Tumor DNA in Colorectal Cancer Patients. Annals of the New York Academy of Sciences, 2006, 1075, 197-203.	1.8	28
192	The metastatic microenvironment: Brainâ€derived soluble factors alter the malignant phenotype of cutaneous and brainâ€metastasizing melanoma cells. International Journal of Cancer, 2012, 131, 2509-2518.	2.3	28
193	Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells. International Journal of Cancer, 1989, 43, 857-862.	2.3	27
194	Production of tumor necrosis factor Î± and interferon Î³ in interleukin-2-treated melanoma patients: Correlation with clinical toxicity. Cancer Immunology, Immunotherapy, 1991, 34, 49-52.	2.0	27
195	Microsatellite Alterations Detected in the Serum of Early Stage Breast Cancer Patients. Annals of the New York Academy of Sciences, 2001, 945, 22-30.	1.8	27
196	Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. Molecular Oncology, 2020, 14, 1760-1778.	2.1	27
197	Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay. , 2000, 88, 1037-1044.		26
198	CD8⁺ Tâ€cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation. European Journal of Immunology, 2015, 45, 71-81.	1.6	26

#	Article	IF	Citations
199	Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients. Cancer Research, 2003, 63, 1884-7.	0.4	26
200	The Use of Molecular Profiling of Early Colorectal Cancer to Predict Micrometastases. Archives of Surgery, 2002, 137, 1377.	2.3	25
201	A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Therapy, 2003, 10, 179-186.	2.2	25
202	Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. Cancer Gene Therapy, 2007, 14, 451-459.	2.2	25
203	A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients. Cancers, 2020, 12, 3361.	1.7	25
204	Modulation of Histamine Type II Receptors on CD8+ T Cells by Interleukin-2 and Cimetidine. International Archives of Allergy and Immunology, 1992, 97, 8-16.	0.9	24
205	Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment. Epigenetics, 2011, 6, 1001-1011.	1.3	24
206	Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunology, Immunotherapy, 1989, 30, 277-282.	2.0	23
207	Transcriptional repression of IFNÎ²1 by ATF2 confers melanoma resistance to therapy. Oncogene, 2015, 34, 5739-5748.	2.6	23
208	ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis. Oncotarget, 2017, 8, 75778-75796.	0.8	23
209	Identification of a Quantitative MINT Locus Methylation Profile Predicting Local Regional Recurrence of Rectal Cancer. Clinical Cancer Research, 2010, 16, 2811-2818.	3.2	22
210	Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy. Clinical Chemistry, 2020, 66, 169-177.	1.5	22
211	Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-ÎºB1 Target SerpinE1 in Aggressive Glioblastoma Tumors. Cancers, 2020, 12, 1081.	1.7	22
212	Clinical Significance of Circulating DNA Microsatellite Markers in Plasma of Melanoma Patients. Annals of the New York Academy of Sciences, 2000, 906, 87-98.	1.8	21
213	High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell and Melanoma Research, 2010, 23, 137-140.	1.5	21
214	A Comparison of Solutions for Lung Preservation Using Pulmonary Alveolar Type II Cell Viability. Annals of Thoracic Surgery, 1988, 45, 643-646.	0.7	20
215	Prognostic molecular biomarkers for cutaneous malignant melanoma. Journal of Surgical Oncology, 2011, 104, 438-446.	0.8	20
216	The RhoJ-BAD signaling network: An Achillesâ€™ heel for BRAF mutant melanomas. PLoS Genetics, 2017, 13, e1006913.	1.5	20

#	Article	IF	Citations
217	RASSF8 regulates progression of cutaneous melanoma through nuclear factor-Î²b. Oncotarget, 2015, 6, 30165-30177.	0.8	19
218	The role of estrogen receptor in melanoma. Expert Opinion on Therapeutic Targets, 2007, 11, 1639-1648.	1.5	18
219	BAG3 protein expression in melanoma metastatic lymph nodes correlates with patientsâ€™ survival. Cell Death and Disease, 2014, 5, e1173-e1173.	2.7	18
220	Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. Epigenomics, 2015, 7, 1303-1311.	1.0	18
221	Hypomethylation of CNTFRÎ± is associated with proliferation and poor prognosis in lower grade gliomas. Scientific Reports, 2017, 7, 7079.	1.6	18
222	Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis. Cancers, 2020, 12, 1692.	1.7	18
223	Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features. Scientific Data, 2018, 5, 180245.	2.4	18
224	Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 2015, 8, 111-118.	3.1	17
225	Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer. Genomics Data, 2017, 12, 14-16.	1.3	17
226	Interleukin-4 plus tumor necrosis factor Î± augments the antigenicity of melanoma cells. Cancer Immunology, Immunotherapy, 1993, 37, 378-384.	2.0	16
227	Analysis of Methylated Circulating DNA in Cancer Patientsâ€™ Blood. Methods in Molecular Biology, 2009, 507, 349-356.	0.4	16
228	Multi-platform genome-wide analysis of melanoma progression to brain metastasis. Genomics Data, 2014, 2, 150-152.	1.3	16
229	Vitamin D deficiency exacerbates UV/endorphin and opioid addiction. Science Advances, 2021, 7, .	4.7	16
230	Reactivity of Neoplastic Cells of Hairy Cell Leukemia with Antisera to S-100 Protein. American Journal of Clinical Pathology, 1987, 88, 86-91.	0.4	15
231	Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A. Cancer Immunology, Immunotherapy, 1992, 34, 419-423.	2.0	15
232	Molecular Lymphatic Mapping of the Sentinel Lymph Node. American Journal of Pathology, 2002, 161, 1153-1161.	1.9	15
233	DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 1581-1593.	2.2	15
234	Chromatin status of apoptosis genes correlates with sensitivity to chemo-, immune- and radiation therapy in colorectal cancer cell lines. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 1769-1778.	2.2	15

#	Article	IF	Citations
235	Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. BMC Cancer, 2018, 18, 1054.	1.1	15
236	Liquid Biopsies for Assessing Metastatic Melanoma Progression. Critical Reviews in Oncogenesis, 2016, 21, 141-154.	0.2	15
237	Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma. Cancer Immunology, Immunotherapy, 1994, 39, 172-178.	2.0	14
238	Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. Breast Cancer Research and Treatment, 2012, 131, 859-869.	1.1	14
239	Epigenetic regulation ofREG1Aand chemosensitivity of cutaneous melanoma. Epigenetics, 2013, 8, 1043-1052.	1.3	14
240	P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway. Cancer Letters, 2017, 407, 66-75.	3.2	14
241	Regeneration Enhances Metastasis: A Novel Role for Neurovascular Signaling in Promoting Melanoma Brain Metastasis. Frontiers in Neuroscience, 2019, 13, 297.	1.4	14
242	Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma. Molecular Oncology, 2021, 15, 1069-1087.	2.1	14
243	Detection of Carcinoembryonic Antigen Messenger RNA in Lymph Nodes from Patients with Colorectal Cancer. New England Journal of Medicine, 1998, 339, 1642-1644.	13.9	13
244	Epigenetics of estrogen receptor-negative primary breast cancer. Expert Review of Molecular Diagnostics, 2012, 12, 371-382.	1.5	13
245	Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease. JCO Precision Oncology, 2018, 2, 1-30.	1.5	13
246	Clonal Origin and Expansions in Neoplasms: Biologic and Technical Aspects Must Be Considered Together. American Journal of Pathology, 2003, 162, 353-355.	1.9	12
247	Molecular markers in malignant cutaneous melanoma: Gift horse or one-trick pony?. Journal of Cellular Biochemistry, 2005, 96, 473-483.	1.2	12
248	Development of Sporadic Microsatellite Instability in Colorectal Tumors Involves Hypermethylation at Methylated-In-Tumor Loci in Adenoma. American Journal of Pathology, 2010, 177, 2347-2356.	1.9	12
249	The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells â€“ a case of interâ€tumor heterogeneity. Molecular Oncology, 2021, 15, 1376-1390.	2.1	12
250	Methylation of p16 and Ras Association Domain Family Protein 1a during Colorectal Malignant Transformation. Molecular Cancer Research, 2006, 4, 303-309.	1.5	11
251	Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform. Frontiers in Bioengineering and Biotechnology, 2020, 8, 581157.	2.0	11
252	Inter-Tumor Heterogeneityâ€”Melanomas Respond Differently to GM-CSF-Mediated Activation. Cells, 2020, 9, 1683.	1.8	11

#	Article	IF	Citations
253	Characterization and augmentation of CD4 + cytotoxic T cell lines against melanoma. Cancer Immunology, Immunotherapy, 1994, 39, 172-178.	2.0	11
254	Isolation of lymphocytes from clotted blood. Journal of Immunological Methods, 1987, 105, 9-14.	0.6	10
255	[27] Assessment of genetic heterogeneity in tumors using laser capture microdissection. Methods in Enzymology, 2002, 356, 302-309.	0.4	10
256	Epigenetics of regional lymph node metastasis in solid tumors. Clinical and Experimental Metastasis, 2012, 29, 747-756.	1.7	10
257	Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients. Advances in Experimental Medicine and Biology, 2018, 1100, 83-95.	0.8	10
258	Circulating Tumor Cells as Prognostic Biomarkers in Cutaneous Melanoma Patients. Methods in Molecular Biology, 2014, 1102, 513-522.	0.4	10
259	Functional interleukin 4 receptor and interleukin 2 receptor common Î³-chain on human nonâ€“small cell lung cancers: Novel targets for immune therapy. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 10-20.	0.4	9
260	Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma?. Nature Clinical Practice Oncology, 2004, 1, 74-75.	4.3	9
261	Molecular Upstaging of Sentinel Lymph Nodes in Melanoma: Where Are We Now?. Surgical Oncology Clinics of North America, 2006, 15, 331-340.	0.6	9
262	Effects of Chemokines on Tumor Metastasis. Cancer Treatment and Research, 2007, 135, 177-184.	0.2	9
263	Multi-modal molecular programs regulate melanoma cell state. Nature Communications, 2022, 13, .	5.8	9
264	Increased metastatic ability and bone formation of a mammary adenocarcinoma in vivo after in vitro passaging. European Journal of Cancer & Clinical Oncology, 1984, 20, 1517-1526.	0.9	8
265	A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine. Cancer, 1993, 72, 750-759.	2.0	8
266	Recognition of gp43 Tumor-Associated Antigen Peptide by both HLA-A2 Restricted CTL Lines and Antibodies from Melanoma Patients. Cellular Immunology, 1997, 178, 162-171.	1.4	8
267	Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy,. Journal of Gastrointestinal Surgery, 2001, 5, 81-90.	0.9	8
268	Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. British Journal of Dermatology, 2012, 166, 1319-1326.	1.4	8
269	EpiMap: Fine-tuning integrative epigenomics maps to understand complex human regulatory genomic circuitry. Signal Transduction and Targeted Therapy, 2021, 6, 179.	7.1	8
270	Interleukin enhancerâ€binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma. Clinical and Translational Medicine, 2021, 11, e608.	1.7	8

#	Article	IF	Citations
271	Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients. Cancers, 2022, 14, 859.	1.7	7
272	Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells. Cellular Immunology, 1990, 128, 516-527.	1.4	6
273	Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Molecular Immunology, 1995, 32, 573-581.	1.0	6
274	Current Status of Human Melanoma Vaccines. BioDrugs, 1997, 7, 66-84.	2.2	6
275	Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine. Journal of Clinical Immunology, 1998, 18, 299-305.	2.0	6
276	Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer. British Journal of Cancer, 1999, 81, 342-349.	2.9	6
277	Overexpression of Î²1,4N-Acetylgalactosaminyl- transferase mRNA as a Molecular Marker for Various Types of Cancers. Oncology, 2002, 62, 149-156.	0.9	6
278	Clinicopathological utility of molecular staging for melanoma patients undergoing sentinel lymphadenectomy. Annals of Surgical Oncology, 2004, 11, 152S-155S.	0.7	6
279	Analysis of Loss of Heterozygosity in Circulating DNA. Methods in Molecular Biology, 2009, 520, 221-229.	0.4	6
280	Direct Serum Assay for MicroRNA in Cancer Patients. Methods in Molecular Biology, 2013, 1024, 147-155.	0.4	5
281	Ganglioside gm2 as a target structure recognized by human natural killer cells. Journal of Clinical Laboratory Analysis, 1987, 1, 209-213.	0.9	4
282	CORRESPONDENCE. Brain Pathology, 2004, 14, 224-224.	2.1	4
283	Hypermethylation of Adenosine Triphosphate-Binding Cassette Transporter Genes in Primary Hyperparathyroidism and Its Effect on Sestamibi Imaging. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1785-1790.	1.8	4
284	Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers. Annals of Surgical Oncology, 2018, 25, 3082-3087.	0.7	4
285	Acetylated DNMT1 Downregulation and Related Regulatory Factors Influence Metastatic Melanoma Patients Survival. Cancers, 2021, 13, 4691.	1.7	4
286	Urine Cell-Free MicroRNAs in Localized Prostate Cancer Patients. Cancers, 2022, 14, 2388.	1.7	4
287	UBQLN4 promotes STING proteasomal degradation during cisplatinâ€induced DNA damage in tripleâ€negative breast cancer. Clinical and Translational Medicine, 2022, 12, .	1.7	4
288	A 6-thioguanine-resistant variant of the rat mammary adenocarcinoma 13762 that is more immunogenic. Cancer Immunology, Immunotherapy, 1987, 24, 42-8.	2.0	3

#	Article	IF	Citations
289	Tumor Necrosis Factor-Î± and Apoptosis Induction in Melanoma Cells through Histone Modification by 3-Deazaneplanocin A. Journal of Investigative Dermatology, 2014, 134, 1470-1473.	0.3	3
290	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 1911-1924.	3.2	3
291	Human IgM antibodies to tumor-associated gangliosides share VHIII (V3-23) and VKIV family subgroups. Immunogenetics, 1998, 48, 73-75.	1.2	2
292	CXCR4 chemokine receptor mediates melanoma and colorectal cancer metastasis to the liver. Journal of the American College of Surgeons, 2004, 199, 81.	0.2	2
293	Molecular Diagnosis of Micrometastasis in the Sentinel Lymph Node. Cancer Treatment and Research, 2005, 127, 221-252.	0.2	2
294	A Multimarker Circulating DNA Assay for Assessing Prostate Cancer Patientsâ€™ Blood. Clinical Chemistry, 2009, 55, 1258-1258.	1.5	2
295	Assessment of Cell-Free microRNA by NGS Whole-Transcriptome Analysis in Cutaneous Melanoma Patientsâ€™ Blood. Methods in Molecular Biology, 2021, 2265, 475-486.	0.4	2
296	Current status of gastrointestinal tract cancer brain metastasis and the use of blood-based cancer biomarker biopsy. Clinical and Experimental Metastasis, 2021, , 1.	1.7	2
297	Microsatellite Alterations as Diagnostic and Prognostic Molecular Markers in Patients With Cancer. , 2004, , 395-428.		2
298	Abstract 4686: MicroRNA mir-93 activates oncogenic c-Met/PI3K/Akt pathway targeting PTEN in hepatocellular carcinoma. , 2014, , .		2
299	Donald Lee Morton: In Memoriam (1934â€“2014). Cancer Research, 2014, 74, 4009-4010.	0.4	1
300	In Situ Sodium Bisulfite Modification of Genomic DNA from Microdissected Melanoma Paraffin-Embedded Archival Tissues. Methods in Molecular Biology, 2015, , 1.	0.4	1
301	Molecular Assessment of Sentinel Lymph Nodes. , 2008, , 206-217.		1
302	Abstract 4665: Quantitative in situ biomarker analysis via ultrasensitive RNA in situ hybridization and automated image analysis. , 2014, , .		1
303	Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients. Cancers, 2021, 13, 91.	1.7	1
304	Prognostic Utility of CpG Island Hypermethylated Phenotype in Early-Stage Invasive Primary Melanomas. Journal of Investigative Dermatology, 2022, 142, 1770-1772.	0.3	1
305	Functional interleukin-4 receptor (IL-4R) and interleukin-2 receptor common gamma chain (IL-2RÎ“C) on human gastric carcinomas: A possible mechanism for cytokine based therapy. Gastroenterology, 2000, 118, A1055.	0.6	0
306	Molecular staging of colon cancer using a novel approach: A multi-center phase II trial. Gastroenterology, 2000, 118, A855.	0.6	0

#	Article	IF	Citations
307	Don Morton. Pigment Cell and Melanoma Research, 2014, 27, 681-682.	1.5	0
308	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2019, , 483-503.		0
309	Ultrastaging of melanoma patients. , 2003, , 148-163.		0
310	Dr. Dave S. B. Hoon. Nishinihon Journal of Dermatology, 2009, 71, 333-334.	0.0	0
311	Circulating Tumor-Related DNA Alterations as Prostate Cancer Biomarkers. , 2010, , 21-27.		0
312	Abstract 3742: FOXC1 is a potential prognostic marker with functional significance in basal-like breast cancer. , 2010, , .		0
313	Abstract 5056: A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairs. , 2012, , .		0
314	Abstract 4350: Low frequencies of SF3B1 mutations indicate SF3B1 inhibitor as a novel moleculartargeted drug for colorectal cancer.. , 2013, , .		0
315	Abstract 668: DNA methylation of apoptosis-related genes as clinical biomarker in rectal cancer.. , 2013, , .		0
316	Abstract 2001: Genomic signatures of melanoma progression and maintenance.. , 2013, , .		0
317	Abstract 3521: B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.. , 2013, , .		0
318	Abstract 3414: Genomic signatures of melanoma maintenance. , 2014, , .		0
319	Abstract 1182: Patient derived xenograft (PDX) of human melanoma to predict clinical responses. , 2014, , .		0
320	Abstract 402: Tumor necrosis factor-alpha and apoptosis induction in melanoma cells through histones modification by 3-deazaneplanocin A. , 2014, , .		0
321	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2017, , 1-21.		0
322	Apoptosis in Cutaneous Melanoma. , 2009, , 111-125.		0
323	The Clinical Use of Molecular Markers as Predictors of Disease Outcome and Response to Therapy in Malignant Melanoma. , 2006, , 551-576.		0
324	A commentary on â€œFAM135B sustains the reservoir of Tip60â€ATM assembly to promote DNA damage responseâ€• Clinical and Translational Discovery, 2022, 2, .	0.2	0